in

FDA Advisers Vote to Replace Original COVID Vaccine With Bivalent Boosters Despite Lack of Clinical Trial Data

FDA Advisers Vote to Replace Original COVID Vaccine With Bivalent Boosters Despite Lack of Clinical Trial Data
FDA Advisers Vote to Replace Original COVID Vaccine With Bivalent Boosters Despite Lack of Clinical Trial Data

Advisers to the U.S. Food and Drug Administration on Thursday voted to replace the original Pfizer and Moderna primary series mRNA COVID-19 vaccines with the bivalent boosters designed to target Omicron variants, despite concerns about insufficient clinical trial data to support safety and efficacy.

What do you think?

Written by colinnew

Leave a Reply

Your email address will not be published. Required fields are marked *

BREAKING: Pfizer RESPONDS to Project Veritas’ ‘Bombshell’ Undercover Video Showing Exec’s Remarks on ‘Mutating’ Viruses

BREAKING: Pfizer RESPONDS to Project Veritas’ ‘Bombshell’ Undercover Video Showing Exec’s Remarks on ‘Mutating’ Viruses

FDA Quietly Changes End Date for Study of Heart Inflammation After Pfizer COVID Vaccination

FDA Quietly Changes End Date for Study of Heart Inflammation After Pfizer COVID Vaccination